The First Affiliated Hospital of Henan University of Science and Technology
The First Affiliated Hospital of Henan University of Science and Technology
Henan, China4 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| The Efficacy and Safety of Inpegsomatropin Injection in Children With Turner Syndrome (TS) and Short Stature | Cardiovascular Abnormalities, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Sex Chromosome Disorders, Turner syndrome, Urogenital Abnormalities, Urogenital Diseases, cardiovascular disorder, chromosomal disorder, congenital heart disease, disorder of sexual differentiation, endocrine system disorder, gonadal disorder, gonadal dysgenesis, heart disorder, hereditary disease, sex chromosome disorder of sex development | Recruiting | Phase 3 | 2026-07-22 | NCT07614152 | |
| Safety, Pharmacokinetic (PK) Profile and Efficacy of Inpegsomatropin Injection in Adults With Growth Hormone Deficiency | Bone Diseases, Developmental, Bone Diseases, Endocrine, Dwarfism, bone disorder, brain disorder, central nervous system disorder, endocrine system disorder, hypopituitarism, hypothalamic disorder, musculoskeletal system disorder, nervous system disorder, pituitary dwarfism, pituitary gland disorder | Recruiting | Phase 2 | 2026-07-22 | NCT07551804 | |
| The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature | Idiopathic Short Stature | Recruiting | Phase 3 | 2026-03-11 | NCT06927310 | |
| The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT) | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Active, not recruiting | Phase 2 / Phase 3 | 2026-01-30 | NCT06921486 |